Danuo Pharmaceutical

On October 16, 2024, Danno Pharmaceutical, an investment company of Aurora Borealis, announced the completion of the first batch of delivery for over 300 million RMB in Series E financing. This round of financing is jointly led by Zhongshan Venture Capital and AMR Action Fund, a subsidiary of Zhongshan Investment Holdings. The funds obtained will be used to support the core new drug research and development pipeline, including the late stage clinical trials and commercialization of TNP-2198, a new drug candidate for treating Helicobacter pylori infection, and TNP-2092, a new drug candidate for treating implanted medical device infection.

Dr. Ma Zhenkun, founder, chairman, and CEO of Danno Pharmaceuticals, said: We are delighted to receive support from Zhongshan Venture Capital and AMR Fund. Danno Pharmaceuticals is committed to addressing the dual challenges of bacterial resistance and tolerance, providing solutions for bacterial infections and metabolic related diseases that still lack rational treatment methods. This round of financing will support Dano Pharmaceuticals in accelerating the commercialization of the new drug candidate TNP-2198 for the treatment of Helicobacter pylori infection, as well as the later clinical trials of the new drug candidate TNP-2092 for the treatment of implanted medical device infections.Zhang Cheng, Chairman of Zhongshan Venture Capital, stated that Dannuo Pharmaceutical focuses on the research and development of new drugs in the field of bacterial infections and microbiota metabolism related diseases. The first new drug product TNP-2198 for the treatment of Helicobacter pylori infection has completed phase III clinical trials, and multiple new drug candidates under development have also entered the later stage of clinical trials. Dannuo Pharmaceutical adopts a differentiated product development strategy to address unmet needs in domestic and international markets, and has broad market prospects. We are delighted to have the opportunity to collaborate with AMR Fund, a leading global investment institution in the field of anti infection, and participate in this round of investment together.

Dr. Henry Skinner, CEO of AMR Fund, the world's largest investment institution in the field of anti infection, said: The current situation of antibiotic resistant bacterial infections worldwide is shocking and increasingly severe. The latest data published in The Lancet shows that by 2050, nearly 40 million people worldwide will die from antibiotic resistant bacterial infections. We are delighted to provide financial support to Danno Pharmaceuticals, and the Danno team is rapidly advancing the development of new antibacterial drugs that have the potential to save the lives of countless patients worldwide and reduce the pain caused by antibiotic resistant bacterial infections.

Danuo Pharmaceutical focuses on bacterial infections and microbiota metabolism related diseases, with a focus on indications that currently lack rational treatment methods and have huge market prospects. Currently, multiple new drug candidates have entered the later stage of clinical trials. Danuo Pharmaceutical adopts a new drug development strategy of first-line therapy to ensure successful commercialization.
TNP-2198 (rifampicin) is a new drug candidate with a unique multi-target synergistic mechanism against microaerophilic and anaerobic bacteria. It is expected to become the world's first new drug product developed for Helicobacter pylori infection in over 30 years, in response to the need for Helicobacter pylori infection screening eradication and prevention strategies in areas with high gastric cancer incidence. Dano Pharmaceuticals has completed 5 Phase I and II clinical trials of TNP-2198 in China, and the Phase III clinical trial is currently nearing completion. Danuo Pharmaceutical has obtained the qualification accreditation of TNP-2198 Qualified infectious diseases Product (QIDP) and Fast Track from the US FDA.
TNP-2092 (rifoquinone) is a novel drug candidate with a unique three target synergistic mechanism, designed to address the dual challenges of antibiotic resistance and tolerance in implanted medical device infections. Dano Pharmaceuticals has completed six Phase I and II clinical trials of TNP-2092 injection in China and the United States, and is preparing to launch an international multicenter Phase III clinical trial for the treatment of artificial joint infections. Dano Pharmaceuticals has obtained the US FDA's QIDP, fast track, and orphan drug qualification for TNP-2092.